Precigen Reports Strong Q1 2026 Results, $21.6M PAPZIMEOS Revenue, Projects Cash Flow Break-Even by Year-End

summarizeSummary

Precigen announced strong Q1 2026 financial results with $21.6 million in PAPZIMEOS product revenue and a significantly reduced net loss, projecting cash flow break-even by year-end 2026.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Reported $21.6 million in net product revenue from PAPZIMEOS in its first full quarter of commercial launch, contributing to a total revenue of $23.252 million.

• Significant Reduction in Net Loss

  Net loss dramatically decreased to $7.9 million ($0.02 per share) in Q1 2026, compared to $54.2 million ($0.18 per share) in Q1 2025.

• Projected Cash Flow Break-Even

  The company anticipates funding its operations to cash flow break-even by the end of 2026, supported by current cash and expected PAPZIMEOS sales.

• PAPZIMEOS Commercial Momentum

  The PAPZIMEOS launch shows strong traction with approximately 400 patients enrolled in the patient hub, broad payer coverage (over 90% of insured US lives), and the implementation of a permanent J-code effective April 1, 2026, streamlining reimbursement.

auto_awesomeAnalysis

Precigen reported significantly improved first-quarter 2026 financial results, driven by the successful commercial launch of PAPZIMEOS, its first FDA-approved product. The substantial reduction in net loss and the projection to reach cash flow break-even by the end of 2026 are critical for the company's financial stability and future operations, especially following a large net loss in 2025.